Medications

PPI use is negative prognostic marker in urothelial cancer

(HealthDay)—For patients with advanced urothelial cancer treated with atezolizumab, proton pump inhibitor (PPI) use is a negative prognostic marker, according to a study published online Sept. 15 in Clinical Cancer Research.

Diseases, Conditions, Syndromes

PPI use doesn't up recurrence of bacterial peritonitis

(HealthDay)—For patients with cirrhosis with previous spontaneous bacterial peritonitis (SBP), proton pump inhibitor (PPI) use is not associated with SBP recurrence, according to a study published online Nov. 7 in the Journal ...

Oncology & Cancer

New guidelines shape the future of neuroendocrine tumor management

Newly updated guidelines on neuroendocrine tumors developed by an expert at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborators provide clinicians with the latest recommendations ...

Pediatrics

Guidelines can cut nonindicated acid-suppressing Rx in infants

(HealthDay)—Implementation of a guideline can reduce nonindicated use of proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) among newborns, according to a study published online Nov. 21 in Pediatrics.

page 17 from 19